edqm
European Directorate for the Quality of Medicines & HealthCare | Direction européenne de la qualité du médicament & soins de santé
COUNCIL OF EUROPE
CONSEIL DE L'EUROPE

Certification of Substances Department

Certificate of suitability
No. R1-CEP 2015-278 - Rev 00

Name of the substance:
PACLITAXEL
Produced by a semi-synthetic process, product code SPT 1308

Name of holder:
SCINOPHARM TAIWAN, LTD.
No. 1, Nan-Ke 8th Road
Taiwan-74144 Shan-Hua, Tainan

Site(s) of production:
SEE ANNEX 1

After e… nd subsequent process… d in annex, we certify … version of the monogr… dition including suppler… the analytical procedu…

– Test for residual solvents by ion chromatography (Annex 2)
  Acetic acid not more than 5000 ppm

– Test for residual solvents by gas chromatography (Annex 3)
  Acetone not more than 5000 ppm
  n-Heptane not more than 5000 ppm

A risk management summary for elemental impurities has been provided. (Annex 4)

The re-test period of the substance is 5 years if stored in double polyethylene bags, placed in a polyethylene drum.

The holder of the certificate has declared the absence of use of material of human or animal origin in the manufacture of the substance.

The submitted dossier must be updated after any significant change that may alter the quality, safety or efficacy of the substance.

Address: 7 Allée Kastner, CS 30026
F-67081 Strasbourg (France)
Tel: +33 (0) 3 88 41 30 30 – e-mail: cep@edqm.eu
Internet: http://www.edqm.eu

Manufacture of the substance shall take place in accordance with the Good Manufacturing Practice and in accordance with the dossier submitted.

Failure to comply with these provisions will render this certificate void.

This certificate is renewed from **6 July 2022** according to the provisions of Resolution AP-CSP (07) 1, and of Directive 2001/83/EC and Directive 2001/82/EC and any subsequent amendment, and the related guidelines.

This certificate has four annexes, the first of 1 page, the second of 3 pages, the third of 4 pages and the fourth of 1 page.

This certificate has:

lines.

On behalf of the
Director of EDQM

Strasbourg, 10 June 2022

DECLARATION OF ACCESS *(to be filled in by the certificate holder under their own responsibility)*

hereby a

to use the above-mentioned certificate of suitability in support of their application(s) for the following Marketing Authorisation(s): (*name of product(s) and marketing number(s), if known*)

The holder also certifies that no significant changes to the operations as described in the CEP dossier have been made since the granting of this version of the certificate.

Date and Signature (*of the CEP holder*):